SLC5A2 and familial primary hypomagnesemia: SGLT2 inhibitors also increased serum magnesium levels in Japanese patients with CKD (median eGFR, 33.5 mL/min/1.73 m2), specifically in patients with hypomagnesemia at baseline [30].